Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for John Murray

19 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

MMCTISS0901-M

03/01/2009

Head and Neck Tumor tissue Repository

Other

VICC090513-M

01/25/2012

Arthralgia in women with early stage breast cancer taking aromatase inhibitors: the Breast Cancer Adjuvant Therapy (BCAT) longitudinal cohort/registry study

Other

MDASUPP0914-M

02/11/2011

A multi-center Study in Patients Undergoing Anthracycline-Based Chemotherapy to Assess the Effectivenessof Using Biomarkers to detect and Identify Cardiotoxicity and Describe Treatment

Other

ECOGBREE2Z04-M

06/11/2008

Quality of LIfe in Younger Breast Cancer Survivors

Other

CTSUBREC70301-M

06/11/2007

Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes

Supportive Care

ALLIANCEA221102-M

11/06/2012

Randomized study of subQ testosterone in the adjuvant treatment of postmenopausal women with aromatase inhibitor induced arthralgias

Treatment

CTSUBRENB-43-M

04/26/2012

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Treatment

CTSUNSABPBREB-47-M

04/26/2012

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

Treatment

CTSUBRENCCTGMA32-M

04/23/2012

A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Treatment

CTSUBRES1007-M

05/25/2011

Phase III randomized trial of standard adjuvant endocrine therapy +/- chemo in patients with 1-3 positive nodes, hormone receptor positive and Her2 negative breast cancer with recurrence score (RS) of 25 or less

Treatment

CTSUGI80702-M

05/05/2011

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer

Treatment

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Treatment

CTSUGIC80802-M

12/07/2010

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Treatment

CTSUBREC40603-M

12/07/2010

Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Treatment

ECOGTHO4508-M

12/07/2010

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

Treatment

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Treatment

ECOGHNE1305-M

02/11/2009

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Treatment

CTSUUROC90203-M

11/05/2007

A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

Treatment

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)